Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine peptidase inhibitor, Kunitz type 3 (SPINT3) is a small protein characterized by the presence of a Kunitz-type domain, approximately 50–60 amino acids in length, stabilized by three disulfide bonds. Kunitz-type domains are canonical proteinase inhibitor motifs, acting primarily by binding the active site of serine proteases to block their catalytic activity. Members of the family play central roles in regulating physiological processes such as blood coagulation, tissue inflammation, and the immune response. In some organisms, they protect against microbial pathogens and facilitate collagen synthesis. SPINT3 and related proteins are notable as therapeutic targets and drug scaffolds, especially for disorders involving proteolytic imbalance such as hereditary angioedema. If further granularity (species, isoform, gene) is needed, additional data sources may clarify exact sequence and functional annotation.
Competitive inhibition of the active site of target serine proteases (e.g., trypsin, kallikrein, elastase) and Allosteric modulation in some cases
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine peptidase inhibitor, Kunitz type 3 (SPINT3).